Abberrant Expression of CD44 in Bile Duct Cancer Correlates with Poor Prognosis

Kunlathida Kunlabut1,4, Kulthida Vaeteewoottacharn1,4, Chaisiri Wongkham1,4, Narong Khuntikeo3,4, Sakda Waraasawapat12,4, Chawalit Pairojkul2,4, Sopit Wongkham1,4*

Abstract

CD44, a transmembrane glycoprotein receptor, plays significant roles in cell migration, differentiation, and survival signaling which are important for both normal and cancer cells. In this study, we examined the expression of all isoforms of CD44 by immunohistochemistry in 3 cases of biliary cystadenoma, 15 cases of non-invasive cystadenocarcinoma (CAC) bile duct tumors, and 67 cases of the aggressive bile duct tumor, cholangiocarcinoma (CCA). Normal bile duct epithelia at different segments along the biliary tree did not express CD44. However, normal biliary cells of the large bile duct adjacent to tumor areas and dysplastic biliary cells in CCA tissues were positive. CD44 was not expressed in cystadenomas and the majority of CACs. Two CAC cases with short survival and the majority of CCA aberrantly expressed CD44. These observations suggest important roles for CD44 in the early stage of carcinogenesis and progression of bile duct cancer. Regardless of the type of bile duct tumor, CAC or CCA patients with positive CD44 expression in biliary epithelia had significant shorter survival than those with negative CD44. Aberrant expression of CD44 in CAC or CCA tissues may indicate an unfavorable patient outcome and may serve as a useful practical adjunct to conventional prognostic indicators for bile duct cancer.

Keywords: CD44, isoform - variant - cholangiocarcinoma - prognosis

Introduction

CD44 is a single pass transmembrane glycoprotein and known as a receptor of hyaluronan (Culty et al., 1990). CD44 expresses in many isoforms according to the cell type and organs. The smallest isoform, is referred as “standard” form (CD44s) and the variant isoforms which are the combination of different alternatively spliced exons, is referred as CD44v (Tolg et al., 1993). CD44 is widely distributed on many cell types and participates in many cellular processes, including the regulation of cell growth, survival, differentiation and motility (Ponta et al., 2003). Alteration of CD44 expression or dysfunction contributes to numerous pathological conditions, including cancers. However, the association of CD44 and its variants with tumor behavior varies depending on tumor type and the organ site of tumor.

Bile duct cancer is a relatively uncommon and poorly understood cancer. There are several types of cancers arise from epithelial cell lining of bile ducts. It can be found as a cystic lesion as cystadenocarcinoma (CAC) or as a more aggressive cancer, cholangiocarcinoma (CCA). A cystic tumor, either benign (cystadenoma) or malignant CAC, is lined by the epithelium with papillary infoldings and is usually multilocular and contains mucoid fluid. On the other hand, CCA arises from any portion of the intra- or extra-hepatic bile duct epithelium and is classified anatomically into intrahepatic CCA and extrahepatic CCA. The intrahepatic CCA can be further classified macroscopically into mass forming, periductal infiltrating and intraductal growth types; which are believed to have different nature and gene expression patterns.

CAC and CCA are relatively rare tumors in most populations. CAC accounts for less than 5% of the reported cystic lesions of the liver (Wheeler and Edmondson, 1985; Devaney et al., 1994), whereas CCA is the second among primary malignant liver tumors; about 15% of liver cancers are estimated to be CCA (Anon., 1990; Parkin et al., 1993; Yamanaka et al., 1995). At the present, detection of bile duct carcinomas is based on clinical examination and imaging techniques; and complete surgical resection is the mainstay of curative treatment with good prognosis. However, because of their rarity and nonspecific presentations, the diagnosis is often delayed resulting in inappropriate treatment modalities, morbidity and mortality (Lempinen et al., 2005; Seidel...
Kunlathida Kunlabut et al

Therefore, it is important to search for a prognostic marker which supports the clinicians for an appropriate and effective judgment of treatment to improve the survival of patients with this malignancy.

There are a few studies on CD44 expression in bile duct cancer. As a general agreement, CD44 is not expressed in normal bile duct epithelium (Ashida et al., 1998; Sato et al., 2006; Pongcharoen et al., 2011). The over-expression of CD44s and various CD44v have been pronounced. CD44v3, v6, and v5 expression was reported to be associated with tumor progression in different CCA types (Ashida et al., 1998; Mikami et al., 2001; Sato et al., 2006). Silencing of CD44 expression resulted in the decreased invasiveness of CCA cell lines in vitro (Pongcharoen et al., 2011).

In this study, we examined the expression of CD44 in two different types of bile duct cancers, CAC, a rare but good prognosis type and CCA, a frequently found with poor prognosis. In addition, 3 cases of biliary cystadenoma were also examined. The results showed that regardless of the nature of the tumors, CD44 expression of tumors indicates aggressiveness and poor outcome of patients.

Materials and Methods

Tissue specimens

Formalin-fixed paraffin embedded tissues were obtained from the tissue bank of the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Thailand. The study was approved by the Khon Kaen University Ethics Committee for Human Research, and the informed consent was obtained from each subject. Tissues included in this study were histologically proved biliary cystadenoma (n=3), CAC (n=15) and CCA (n=67). Tumor staging was judged according to TNM classification by the American Joint Committee 6th edition in the year 2006 (Greene and American Joint Committee on Cancer, 2006). Histopathological grading of CCA was done according to the WHO classification (Bosman et al., 2000) as papillary and non-papillary type. As a representative of normal bile duct, haemangioma liver (n =10) sections were used to examine the CD44 expression in the biliary epithelium along the biliary tree.

The 3 cystadenoma cases were all males with median age of 62 years (ranged 52-66 years); CAC cases were 2 males and 13 females (male:female=0.15:1) with median age of 51 years (ranged 36-70 years); and CCA were 41 males and 26 females (male:female=1.6:1) with median age of 56 years (ranged 39-75 years). Clinical data were reviewed from the medical records and the overall survivals were recorded from the date of operation till 25 April 2011. Survivals of all patients were more than 60 days and hence no peri-operative death was observed in our series.

Immunohistochemistry

The immunohistochemical staining of CD44 was performed according to the standard protocol. The expression of CD44 was examined using monoclonal antibody (IM7; Biolegend, San Diego, CA) which detects all isoforms of CD44. Briefly, the deparaffinized tissue sections were treated with 0.3% H2O2 for 30 min to block endogenous peroxidase activity and heated with 10 mM Tris-EDTA buffer, pH 9.0 in a pressure cooker for 3 min to enhance antigen expression. The slides were incubated with 1:25 diluted rat anti-CD44 monoclonal antibody at room temperature, overnight and with 1:100 diluted HRP-conjugated goat anti-rat IgG (Zymed Laboratories; San Francisco, CA) at room temperature, for 2 h. The peroxidase activity was visualized using diaminobenzidine tetrahydroxychloride solution (DAB; Dako; Glostrup, Denmark).

The expression of CD44 was evaluated independently by two observers who were blinded to the clinical outcome and the results were graded into either the negative group with no CD44 expression or the positive group with various expression of CD44.

Statistical analysis

The statistical significance between the presence of CD44 and the clinicopathological factors was determined using the chi-square test. The overall survival was calculated according to the Kaplan-Meier method and the log-rank test was used for statistical comparisons between curves. Multivariate analysis was performed using Cox proportional hazard model. P value<0.05 was considered statistically significant.

Results

CD44 expression in cystadenoma and CAC

We first examined the CD44 expression in the biliary...
epithelium along the biliary tree of haemangioma livers (n=10) which were used as a representative of normal bile duct. Bile duct epithelia found in interlobular bile ducts, septal ducts, segmental ducts and large bile ducts were all negative for CD44. Bile duct epithelia, arteriole and vein in portal triad and hepatocytes (Figure 1A), septal bile duct (Figure 1B) and large bile duct (Figure 1C) were negative for CD44, whereas Kuffer cells and infiltrating lymphocytes were positive.

Biliary epithelia of all cystadenoma (n=3; Figure 2A) and 86.6% (13/15) of CAC (Figure 2B) were negative for CD44. Focal staining of CD44 expression with strong intensity was detected in two cases of CAC (Figure 2C-D). CD44 expression in CCA

In CCA tissues, most of the normal large bile ducts (10/12, 83.3%) located in the non-tumor area adjacent to the tumor front were positive for CD44 (Figure 3A). CD44 was aberrantly expressed in dysplastic bile ducts (Figure 3B) and CCA tumor cells with varied frequency and intensity. Of 67 CCA, 37 cases (55%) had aberrant expression of CD44, whereas 30 cases (45%) were negative. Most of the CD44 expression detected in CCA tissues were seen as membranous staining pattern regardless of histological types of the tumor; papillary CCA (Figure 3C-D), well-differentiated (Figure 3E) and poorly-differentiated CCA (Figure 3F).

Association of aberrant expression of CD44 in bile duct epithelia with patients’ poor outcome

We analyzed further the association of CD44 expression and clinico-pathological features of patients. Since only 2 out of 15 CAC patients exhibited CD44 expression, the univariate analysis of CAC patients was not assessed. The univariate analysis of 67 CCA patients revealed no correlation between CD44 expression and clinico-pathological factors including age, gender, tumor gross type, tumor size, histological type, or tumor stage (Table 1). However, two-year survival of patients with CD44 negative (9/29, 31%) was significantly higher than those with CD44 positive (3/37, 8%) (P=0.027).

Survival analysis using Kaplan-Meier plot and Log-Rank test revealed that two CAC patients with positive CD44 had a worse survival than those with negative CD44 (n=13) (P=0.0415; Figure 4A). The mean survival times of patients with positive vs. negative CD44 expression were 247 days (95% CI; 59-435 days) vs. 1,119 days (95%CI; 649-1,590 days), respectively. For CCA patients, 59 of 67 patients (88%) died during the follow-up period. The overall survival of patients with positive CD44 expression was compared to those with negative expression (Figure 4B). The log-rank test indicated that the survival time of patients with positive CD44 expression (mean survival 345 days, 95% CI=238-451 days) was significantly shorter than patients with negative CD44 expression (mean survival 675 days, 95% CI=278-1,072 days) (P=0.041). The mean survival times of patients with positive vs. negative CD44 expression were 345 days, 95% CI=238-451 days) vs. 675 days (95% CI=278-1,072 days), respectively.

Table 1. Correlation between CD44 Expression and Clinico-pathological Factors of CCA Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>N</th>
<th>CD44 expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>CD44 expression</td>
</tr>
<tr>
<td>Age ≤ 56 years</td>
<td>37</td>
<td>16</td>
</tr>
<tr>
<td>&gt; 56 years</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>Gender Female</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td>Male</td>
<td>41</td>
<td>19</td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECC</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>ICC</td>
<td>54</td>
<td>26</td>
</tr>
<tr>
<td>Gross type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MF</td>
<td>53</td>
<td>22</td>
</tr>
<tr>
<td>others</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 5 cm.</td>
<td>21</td>
<td>12</td>
</tr>
<tr>
<td>&gt; 5 cm.</td>
<td>46</td>
<td>18</td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>27</td>
<td>10</td>
</tr>
<tr>
<td>Non-papillary</td>
<td>40</td>
<td>20</td>
</tr>
<tr>
<td>Tumor stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-IIIC</td>
<td>33</td>
<td>14</td>
</tr>
<tr>
<td>IV</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>Lymph node invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>30</td>
<td>12</td>
</tr>
<tr>
<td>absent</td>
<td>37</td>
<td>18</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>absent</td>
<td>52</td>
<td>25</td>
</tr>
<tr>
<td>Neural invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>absent</td>
<td>66</td>
<td>30</td>
</tr>
<tr>
<td>Survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 2 years</td>
<td>55</td>
<td>21</td>
</tr>
<tr>
<td>≥ 2 years</td>
<td>12</td>
<td>9</td>
</tr>
</tbody>
</table>

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.KKSuppl.95

Aberrant Expression of CD44 in Bile Duct Cancer Correlates with Poor Prognosis
Kunlathida Kunlabut et al.

Discussion

CD44, a receptor for hyaluronan, is a transmembrane glycoprotein (Culty et al., 1990) and participates in the regulation of many cellular processes including cell growth, survival, differentiation and motility (Ponta et al., 2003). Because of such diverse roles in regulation of cellular functions, CD44 is considered to involve in carcinogenesis and tumor progression. In this study, we analyzed the CD44 expression in two types of bile duct cancers, CAC and CCA, by an immunohistochemical method using an antibody recognizing all CD44 isoforms. The results of this study show that CD44 was aberrantly expressed in CCA cells, but not in CAC cells. Up-regulation of CD44 has been shown in many types of tumors, such as cancer of breast (Bankfalvi et al., 1998), colon (Imazeki et al., 1996), and thyroid (Figge et al., 1994), etc. These results emphasize the possibility of essential roles of CD44 in carcinogenesis regardless of tumor origin.

In the present study, aberrant expression of CD44 was observed not only in CCA cells but also the epithelia of large bile duct located in the non-tumor tissues adjacent to tumor front and dysplastic bile duct epithelia of CCA tissues. This observation is consistent with the previous reports that CD44 expression was obviously found in CCA related inflammatory biliary diseases, e.g., primary sclerosing cholangitis and primary biliary cirrhosis (Cruickshank et al., 1998; 1999). Similar phenomena were observed in many cancers such as colon carcinoma. CD44 expression was increased during carcinogenesis and tumor progression of colon cancer. CD44 was rarely expressed in normal epithelia but it was gradually expressed through the pre-malignant lesions, in early and late adenoma, carcinoma and increasing at more advanced stage of colon cancer (Wielenga et al., 1993). These results imply the possible significant role of CD44 in the early stages of carcinogenesis of CCA and other cancers.

CD44 is a multifunctional molecule involved in cellular adhesion, migration and invasion which are important in cancer progression. Association of CD44 expression with tumor progression and metastasis were shown in many reports (Mikami et al., 2001; Sato et al., 2006). In the present study, the association of CD44 expression and the patients’ poor outcome was evident in two types of bile duct cancers, namely CAC and CCA, suggesting the important role of CD44 in tumor development and progression in these malignancies. According to different cell type or organ origin, CD44 may function in coordination with different cellular machineries resulting in different response and final outcome. Up-regulation of CD44 and its specific isoforms in association with an unfavorable outcome were reported in gastric cancer (Ghaffarzadehgan et al., 2008), hepatocellular carcinoma (Endo and Terada, 2000), and osteosarcoma (Kim et al., 2002). In contrast, down-regulation of CD44 expression associated with an unfavorable outcome of patients was also demonstrated in a number of cancers, e.g., prostate cancer (Aaltomaa et al., 2001), melanoma (Karjalainen et al., 2000) and neuroblastoma (Munchar et al., 2003). Aberrant expression of CD44s significantly correlated with absence of metastasis and vascular invasion has been reported for non-liver fluke associated CCA (Ashida et al., 1998).

CD44 is a highly polymorphic protein due to the diverse alternative splicing of 10 variant exons in the extracellular portion of the protein. While the standard CD44 is widely expressed in particular cells and tissues, the expression of CD44 and its variants in association with cancer progression have been variably reported in the past decade. Recently, expression of CD44 in association with invasiveness was shown in human CCA cell lines (Pongcharoen et al., 2011). Silencing of CD44 by siRNA to all CD44 isoforms significantly reduced cell migration and adhesion. The insertion of variant regions into CD44 may confer distinct properties to CD44v such as a reduced affinity for hyaluronan and the ability to form homotypic interactions with CD44 on neighboring cells (Bennett et al., 1995; Droll et al., 1995). Various CD44 isoforms (CD44s, CD44v5, CD44v6, CD44v7-8, and CD44v10) with different frequency (13%-49%) were reported in CCA tissues (Ashida et al., 1998). Our preliminary study using semi-qRT-PCR of CAC and CCA tissues with positive CD44 immunohistochemistry revealed that these bile duct cancers had similar patterns of CD44s and CD44v. The association of specific CD44v and function in CCA is now under investigated.

Currently, CD44 is proposed to be one of the candidate molecules for the therapeutic target. Enforced expression of miR-34a, the key negative regulator of CD44 could inhibit clonogenic expansion, tumor regeneration and metastasis in prostate cancer cells in vitro and in vivo (Liu et al., 2011). Because different tumors may have distinct CD44 isoforms that interact with discrete ligands, it is necessary to characterize these molecules in a specified cancer before any attempts at targeting.

In conclusion, CD44 was aberrantly expressed in precancerous and tumor bile duct epithelia. Regardless of tumor type, expression of CD44 in bile duct cancer was associated with patients’ poor outcome. CD44 expression may offer useful prognostic information and can serve as an important practical adjunct to conventional histopathological examination of bile duct cancer.

Acknowledgements

This research was supported by the Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, through the Health cluster (SHeP-GMS) and the Faculty of Medicine, Khon Kaen University. KK is supported by the Ph.D.-MD. Program, Faculty of Medicine, Khon Kaen University and Pfizer Thailand Foundation. The authors would like to thank Prof. Y. Nawa for critical comment and English-language presentation of the manuscript. In addition we wish to acknowledge the support of the Khon Kaen University Publication Clinic, Research and Technology Transfer Affairs, Khon Kaen University, for their assistance.
Aberrant Expression of CD44 in Bile Duct Cancer Correlates with Poor Prognosis

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.KKSuppl.95

References


